Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 3/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanedioate SCHEMBL6536627 | 1.00 | TSHR (0.44) | TSHRLMNANFKB1PMP22PTGS1 | |
| Propionic Acid SCHEMBL22749330 | 0.81 | FFAR3 (0.40) | KMT2AALDH1A1 | |
| SCHEMBL36368 | 0.79 | PARL (0.43) | — | |
| SCHEMBL28063863 | 0.78 | TSHR (0.38) | TSHRLMNANFKB1PMP22PTGS1 | |
| Octanedioate SCHEMBL7080168 | 0.78 | TSHR (0.55) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL29748565 | 0.77 | PARL (0.46) | LMNA | |
| SCHEMBL1841389 | 0.77 | LMNA (0.36) | TSHRLMNANFKB1PMP22PTGS1 | |
| Tetraxetan SCHEMBL3797845 | 0.76 | HSD17B10 (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| Octanedioate SCHEMBL6037661 | 0.76 | TSHR (0.52) | TSHRLMNANFKB1PMP22PTGS1 | |
| Azelaic Acid SCHEMBL28918234 | 0.76 | TSHR (0.52) | TSHRLMNANFKB1PMP22PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331037-B2 | Pyrimidines as EGFR-inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20210078977-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10870636-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190194169-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10266517-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170362204-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| WO-2016105525-A2 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20090169593-A1 | METHOD OF USING AND PRODUCING TROPOELASTIN AND TROPOELASTIN BIOMATERIALS | BIOMEDICAL RESEARCH SERVICES, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | TSHR 1554/4885LMNA 4109/4885NFKB1 2977/4885 |
| US-20170362204-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | TSHR 1385/4885LMNA 3948/4885NFKB1 2841/4885 |
| US-20210078977-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | TSHR 1385/4885LMNA 3948/4885NFKB1 2841/4885 |
| US-20190194169-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | TSHR 1385/4885LMNA 3948/4885NFKB1 2841/4885 |
| US-10870636-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | TSHR 1867/4885LMNA 3703/4885NFKB1 3065/4885 |
| US-12331037-B2 | Pyrimidines as EGFR-inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | TSHR 1755/4885LMNA 3567/4885NFKB1 3311/4885 |
| US-10266517-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | TSHR 1867/4885LMNA 3703/4885NFKB1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.